October 25, 2024 11:27 AM EDTUpdated 02:15 PM

Tyra's stock dips as it gives first look in challenge to J&J’s bladder cancer drug Balversa

Lei Lei Wu

News Reporter

Tyra Biosciences unveiled early trial results on its FGFR3-specific inhibitor in advanced bladder cancer patients on Friday, the public company’s first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tyra's stock dips as it gives first look in challenge to J&J’s bladder cancer drug Balversa

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Revolution Medicines breaks ground in challenging pancreatic cancer with two RAS drugs

Iterum wins approval for new oral antibiotic for UTIs. Now it wants a partner

Elucida Oncology, seeking foothold in ADCs, shutters due to 'lack of funding'

Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson

Lyell Immunopharma to acquire ImmPACT Bio, cut top programs

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Tyra's stock dips as it gives first look in chal­lenge to J&J’s blad­der can­cer drug Balver­sa

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Tyra's stock dips as it gives first look in challenge to J&J’s bladder cancer drug Balversa